Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Q4 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript

Feb 28, 2024 / 09:30PM GMT
Release Date Price: €27 (+2.27%)
Operator

Good afternoon, ladies and gentlemen. Thank you for joining today's Mirum Pharmaceuticals reports Q4 year end 2023 financial results and provides business update. My name is Tia, and I will be your moderator for today's call. (Operator instructions)

It is my pleasure to pass the call over to Andrew McKibben, Vice President of Investor Relations and Finance. Please proceed.

Andrew McKibben
Mirum Pharmaceuticals Inc - VP, IR and Finance

Thanks, Tia, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals fourth-quarter 2023 conference call. I'm joined today by our CEO, Chris Peetz; President and Chief Operating Officer, Peter Radovich; our Chief Scientific Officer and Head of Research, Pam Vig; our Chief Medical Officer Joanne Quan; and Eric Bjerkholt, our Chief Financial Officer.

Earlier today, Mirum issued a news release announcing the company's results for the fourth-quarter and full-year 2023. Copies of this news release and SEC filings can be found in the Investors section of our website.

Before we begin,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot